Surgery for Stage IV Gastric Cancer After Immunotherapy: A Case Report
Author Information
Author(s): Evdokimova Sevindzh F., Kornietskaya Anna L., Bolotina Larisa V., Kolobayev Iliya V., Fedenko Alexander A., Kaprin Andrey D.
Primary Institution: P. Hertsen Moscow Oncology Research Institute
Hypothesis
Can conversion surgery improve survival outcomes for patients with stage IV gastric cancer after third-line immunotherapy?
Conclusion
The patient remained disease-free for 22 months after conversion surgery following third-line immunotherapy.
Supporting Evidence
- The patient had a complete response to pembrolizumab before surgery.
- Conversion surgery was performed without evidence of disease for 22 months post-operation.
- The case highlights the potential for surgery after immunotherapy in advanced gastric cancer.
Takeaway
A patient with advanced stomach cancer had surgery after treatment with a drug called pembrolizumab and stayed healthy for almost two years after the surgery.
Methodology
The patient underwent conversion surgery after showing a complete response to pembrolizumab treatment.
Potential Biases
Potential bias due to the lack of a control group and reliance on a single patient's outcome.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
A 67-year-old male patient with stage IV gastric cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website